S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver

Apellis Pharmaceuticals Stock Price, News & Analysis (NASDAQ:APLS)

$61.58
+7.71 (+14.31%)
(As of 12/1/2023 ET)
Compare
Today's Range
$53.30
$61.69
50-Day Range
$37.14
$61.58
52-Week Range
$19.83
$94.75
Volume
5.43 million shs
Average Volume
1.69 million shs
Market Capitalization
$7.30 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$66.50

Apellis Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
8.0% Upside
$66.50 Price Target
Short Interest
Bearish
13.62% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.27
Upright™ Environmental Score
News Sentiment
0.94mentions of Apellis Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$2.96 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.59) to ($1.91) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

604th out of 951 stocks

Pharmaceutical Preparations Industry

279th out of 431 stocks


APLS stock logo

About Apellis Pharmaceuticals Stock (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA). The company also develops APL-2006, a bispecific C3 and VEGF inhibitor for treating wet age-related macular degeneration and GA; APL-1030, a C3 inhibitor for the treatment of various neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

APLS Stock Price History

APLS Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
APLS Jan 2025 120.000 put
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Apellis Pharmaceuticals Inc APLS
21 Analysts Have This to Say About Apellis Pharmaceuticals
APLS Oct 2023 43.000 call
See More Headlines
Receive APLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
12/02/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/20/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APLS
Fax
N/A
Employees
767
Year Founded
2009

Price Target and Rating

Average Stock Price Target
$66.50
High Stock Price Target
$93.00
Low Stock Price Target
$29.00
Potential Upside/Downside
+8.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
14 Analysts

Profitability

Net Income
$-652,170,000.00
Net Margins
-222.16%
Pretax Margin
-222.37%

Debt

Sales & Book Value

Annual Sales
$75.42 million
Book Value
$1.96 per share

Miscellaneous

Free Float
109,613,000
Market Cap
$7.30 billion
Optionable
Not Optionable
Beta
0.96

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report














APLS Stock Analysis - Frequently Asked Questions

Should I buy or sell Apellis Pharmaceuticals stock right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last twelve months. There are currently 3 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" APLS shares.
View APLS analyst ratings
or view top-rated stocks.

What is Apellis Pharmaceuticals' stock price target for 2024?

14 brokers have issued 12-month target prices for Apellis Pharmaceuticals' stock. Their APLS share price targets range from $29.00 to $93.00. On average, they anticipate the company's share price to reach $66.50 in the next year. This suggests a possible upside of 8.0% from the stock's current price.
View analysts price targets for APLS
or view top-rated stocks among Wall Street analysts.

How have APLS shares performed in 2023?

Apellis Pharmaceuticals' stock was trading at $51.71 at the start of the year. Since then, APLS stock has increased by 19.1% and is now trading at $61.58.
View the best growth stocks for 2023 here
.

When is Apellis Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 20th 2024.
View our APLS earnings forecast
.

How were Apellis Pharmaceuticals' earnings last quarter?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) posted its quarterly earnings data on Wednesday, November, 1st. The company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($0.88) by $0.29. The company earned $110.40 million during the quarter, compared to analysts' expectations of $99.05 million. Apellis Pharmaceuticals had a negative trailing twelve-month return on equity of 209.10% and a negative net margin of 222.16%. The firm's quarterly revenue was up 400.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.75) earnings per share.

What ETFs hold Apellis Pharmaceuticals' stock?
What is Cedric Francois' approval rating as Apellis Pharmaceuticals' CEO?

18 employees have rated Apellis Pharmaceuticals Chief Executive Officer Cedric Francois on Glassdoor.com. Cedric Francois has an approval rating of 100% among the company's employees. This puts Cedric Francois in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Apellis Pharmaceuticals to a friend.

What other stocks do shareholders of Apellis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include AbbVie (ABBV), OPKO Health (OPK), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM) and BioXcel Therapeutics (BTAI).

When did Apellis Pharmaceuticals IPO?

(APLS) raised $150 million in an initial public offering (IPO) on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI acted as the underwriters for the IPO.

Who are Apellis Pharmaceuticals' major shareholders?

Apellis Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Jennison Associates LLC (3.01%), FMR LLC (1.91%), Morgan Stanley (1.36%), Polar Capital Holdings Plc (0.89%), Assenagon Asset Management S.A. (0.87%) and Fiera Capital Corp (0.78%). Insiders that own company stock include A Sinclair Dunlop, Adam J Townsend, Alec Machiels, Cedric Francois, David O Watson, Federico Grossi, James George Chopas, Jeffrey Eisele, Karen Lewis, Lukas Scheibler, Mark Jeffrey Delong, Morningside Venture Investment, Nicole D Perry, Nur Nicholson, Pascal Deschatelets, Timothy Eugene Sullivan and Victoria L Brown.
View institutional ownership trends
.

How do I buy shares of Apellis Pharmaceuticals?

Shares of APLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Apellis Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Apellis Pharmaceuticals: APL DEL Holdings II LLC, APL DEL Holdings LLC, APL PRG I Corp., APL Sales I LLC, Apellis Australia Pty Ltd., Apellis Bermuda Ltd., Apellis Cayman Holdings Limited, Apellis France S.A.S., Apellis Germany GmbH, Apellis Ireland Ltd., Apellis MA Securities Inc., Apellis Netherlands B.V., Apellis Switzerland GmbH, Apellis U.K. Limited, and Potentia Pharmaceuticals.
Read More
This page (NASDAQ:APLS) was last updated on 12/3/2023 by MarketBeat.com Staff

My Account -